3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Breast Neoplasms
9
Melanoma
4
Neoplasms
3
Multiple Myeloma
3
Skin Neoplasms
2
Polycystic Ovary Syndrome
2
Venous Thromboembolism
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Renal Insufficiency
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Obesity
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Meningioma
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Inflammation
1
Interventions
Vitamin D
2
Tirzepatide
2
Metformin
2
licogliflozin
1
indole-3-carbinol
1
bupropion hydrochloride, naltrexone hydrochoride drug combination
1
Tablets
1
Specimen Handling
1
Resistance Training
1
Progestins
1
Pregabalin
1
Orlistat
1
Organizational Objectives
1
Omeprazole
1
Observation
1
Naltrexone
1
Ketorolac
1
Exergaming
1
Exercise
1
Exenatide
1
Diet, Plant-Based
1
Dexmedetomidine
1
Dalteparin
1
Counseling
1
Cholecalciferol
1
Calcium Citrate
1
Calcium Carbonate
1
Calcitriol
1
CKD732
1
Bupropion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Obesity
×
Tablets
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled